Corporation
Hoffmann-La Roche Limited
- Meetings this Parliament
- 26
- With MPs
- 10
- Since Nov 2021
- 168
- Active registrations
- 1
Most recent reported meeting: Sep 29, 2026.
Lobbying by Hoffmann-La Roche Limited: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 30, 2026
Filed by Stefanos Tsamousis, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Lobbyists
- Bill Zindle · Executive Director, Strategy and Marketing
- Cassondra McCrory · Healthcare System Partner Federal
- Donna Janzen · Director Regulatory Strategy & Policy
- Michele D'Elia · Executive Director, Medical & Scientific Affairs
- Roger Tam · Vice President, Legal
- Shikha Virdi · Chapter Lead, Policy & Healthcare Ecosystems
- Stefanos Tsamousis · PRESIDENT AND CHIEF EXECUTIVE OFFICER
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Environment and Climate Change Canada (ECCC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (15)Hide details
- The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States.
- Pharmaceutical intellectual property protection as it relates to international trade agreements
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
- Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
- Food and Drugs Act updates, as it relate to the reform of clinical trial applications, and drug/device submission review and approval process. Scope includes new drug submissions/indications and post market submissions, reliance & recognition pathways, service standards, fees, biosimilars, clinical trial modernization.
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Standing Committee on Finance (FINA) as it relates to pre-budget consultations.
- The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy.
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
- Income Tax Act as it relates to biopharmaceutical industry.
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
- House of Commons Standing Committee of Industry and Technology (INDU) as it relates to Artificial Intelligence and/or any other pertinent legislative proposal before the committee
- Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
- Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
- Clinical Trials environment in Canada: operational issues, investment, enrollment
Registration 966507-64-73. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Brigitte Nolet (114), Ronnie Miller (39), Stefanos Tsamousis (8), Dan Edgcumbe (7).
-
Reported by Brigitte Nolet · In-house (corporation)
- David Lee · Chief Regulatory Officer, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Patrick Wittmann · Ambassador of Canada to Switzerland and Liechtenstein, Global Affairs Canada (GAC)
- Nadja Schauer · Counsellor (Commercial) and Senior Trade Commissioner, Global Affairs Canada (GAC)
- Matthew Peters · Head of Investment, Global Affairs Canada (GAC)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
and 8 moreShow fewer
- Jocelyn Milburn · Director, Innovation, Science and Economic Development Canada (ISED)
- Stacey Mantha · Interim Director General (Representing Stephen Bent), Public Health Agency of Canada (PHAC)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
- Heather Deehan · Director, Public Health Agency of Canada (PHAC)
- Cheryl Marinsky · Policy Analyst, Public Health Agency of Canada (PHAC)
- Andrea Knight · Special Advisor, HERC, Innovation, Science and Economic Development Canada (ISED)
- Fern Bannatyne · Associate Director, Public Health Agency of Canada (PHAC)
- Sylvain Roussel · Acting Director, Health Canada (HC)
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade, establishment of an approval framework for subsequent entry biologic products, provision of data exclusivity for innovative drug products, review and approval of new drug submissions and post market surveillance of drug products and/or data protection and the regulation and protection of biopharmaceutical products. Read more
Policies related to the importation of pharmaceuticals from Canada to the United States
-
Reported by Brigitte Nolet · In-house (corporation)
- Sarah Lawley · ADM, Health Canada (HC)
- Sarah Lawley · ADM, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
Policies related to the importation of pharmaceuticals from Canada to the United States
-
Reported by Brigitte Nolet · In-house (corporation)
- Mélanie Joly · Minister of Foreign Affairs
House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee Read more
-
Reported by Brigitte Nolet · In-house (corporation)
- Jennings Phillip · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
-
Reported by Brigitte Nolet · In-house (corporation)
- Tanya Ramsamy · Director, PDD, Health Canada (HC)
- Martin McLean · Director, PDD, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Tanya Ramsamy · Director, PDD, Health Canada (HC)
- Martin McLean · Director, PDD, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- David Lee · Chief Regulatory Officer, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Lee David K · Chief Regulatory Office, Health Product and Food Branch, Deputy Minister's Office, Health Canada (HC)
- Alysha Croker · Director, BRDD, Centre for Policy, Pediatrics and International Collaboration, Health Canada (HC)
- Patricia Dechman · Acting Associate Director, Policy, Planning & International Affairs Directorate, Health Canada (HC)
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
-
Reported by Brigitte Nolet · In-house (corporation)
- Sophie Sommerer · Director General, BRDD (Biologics and Radiopharmaceutical Drug Directorate), Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
- Joyce Boye · Director General, Food & Nutrition Directorate, Health Canada (HC)
- Ed Morgan · Director General, Policy Planning & International Affairs Directorate, Health Canada (HC)
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
-
Reported by Brigitte Nolet · In-house (corporation)
- Melisssa Sutherland · A/ Director General, Health Canada (HC)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
- Greg Orencsak · Deputy Minister of Health, Health Canada (HC)
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
-
Reported by Brigitte Nolet · In-house (corporation)
- Jeannine Ritchot · Assistant Deputy Minister, Privy Council Office (PCO)
Strategic Innovation Fund, as it relates to any initiative submitted or supported
-
Reported by Brigitte Nolet · In-house (corporation)
- Elizabeth Troller · Director General, Health Care Strategies, Health Canada (HC)
- Jessica Thomson · Senior Policy Analyst, Health Canada (HC)
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
-
Reported by Brigitte Nolet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Brigitte Nolet · In-house (corporation)
- Sophie Sommerer · Director General, BRDD, Health Canada (HC)
- Karen Reynolds · Director General, PDD, Health Canada (HC)
- Kelly Robinson · Director General, MHPD, Health Canada (HC)
- Tamara Ramsey · Exec Director, PDD (ACCESS Consortium Lead), Health Canada (HC)
Science and Technology
-
Reported by Brigitte Nolet · In-house (corporation)
- Jessica Fullerton · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Health
-
Reported by Brigitte Nolet · In-house (corporation)
- Marie-Françoise Mégie · Senator, Senate of Canada
Health
-
Reported by Brigitte Nolet · In-house (corporation)
- Yash Nanda · Senior Advisor to the Minister of Finance, Finance Canada (FIN)
Economic Development
-
Reported by Brigitte Nolet · In-house (corporation)
- Nick Kang · Senior Policy ADvisor, Prime Minister's Office (PMO)
Economic Development
-
Reported by Brigitte Nolet · In-house (corporation)
- Rechie Valdez · Member of Parliament
- Ajay Rakhra · Senior Advisor, Ontario and Stakeholder Relations, Innovation, Science and Economic Development Canada (ISED)
- Christina Osei · Digital Communications Advisor, Innovation, Science and Economic Development Canada (ISED)
- Chris Zhou · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Brigitte Nolet · In-house (corporation)
- Kim Pate · Senator, Senate of Canada
Health
-
Reported by Brigitte Nolet · In-house (corporation)
- Chris Forbes · Deputy Minister, Finance Canada (FIN)
- Alison O'Leary · Assistant Deputy Minister, Finance Canada (FIN)
Economic Development
-
Reported by Brigitte Nolet · In-house (corporation)
- Mark Holland · Minister of Health, Health Canada (HC)
- Eshan Naik · Director of Policy, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.